Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Nordisk
Biotech
Novo expands pivotal program after amycretin shines in diabetes
After posting phase 2 data, Novo has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity prospect.
Nick Paul Taylor
Nov 25, 2025 7:44am
Fierce Pharma
Novo reports 2 trial failures for GLP-1 in Alzheimer's disease
Nov 24, 2025 11:41am
Pfizer finalizes Metsera buy after contentious Novo bidding war
Nov 13, 2025 12:43pm
Korro lays off staff as lead drug disappoints, Novo pauses pact
Nov 13, 2025 7:20am
Novo Nordisk shares mixed data behind pivotal heart disease push
Nov 11, 2025 8:32am
Pfizer beats out Novo with $10B agreement to buy Metsera
Nov 8, 2025 8:11am
